详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China. [3]South Sichuan Institute of Translational Medicine, Luzhou, China. [4]Department of Pharmacy, The Second People's Hospital of Jiangyou, Mianyang, China. [5]Department of Pharmacy, The People's Hospital of Wusheng, Guang'an, China. [6]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

出处：

DOI：

ISSN：

关键词： hypoxia-inducible factors breast cancer drug delivery systems tumor microenvironment angiogenesis glycolysis

摘要：

Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.Copyright © 2022 Luo, Jiang, Anfu Zheng, Zhao, Wu, Li, Du, Chen, Deng, Chen, Li, Li, Gu, Sun, Xiao and Shen.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区药学

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China. [3]South Sichuan Institute of Translational Medicine, Luzhou, China. [4]Department of Pharmacy, The Second People's Hospital of Jiangyou, Mianyang, China.

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China. [3]South Sichuan Institute of Translational Medicine, Luzhou, China. [6]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]乳腺癌相关成纤维细胞：乳腺癌治疗的新靶点 [2]Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. [3]Preparation and application of pH-responsive drug delivery systems. [4]外泌体作为药物传递系统的前景及挑战 [5]Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. [6]外泌体作为药物传递系统的前景及挑战 [7]Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia [8]PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications. [9]Double-catheter intrathecal targeted drug delivery systems for the treatment of neck and abdominal cancer pain [10]The role of microRNAs in the gastric cancer tumor microenvironment